2022 Cellular Therapy Conference Webcast

This accredited continuing education activity “2022 Cellular Therapy Conference Webcast”, is recorded from the live course held on 9/9-10/2022. 

If you participated in the live course titled - 2022 Cellular Therapy Conference on 9/9-10/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that course on 9/9-10/2022. However, you can still enroll in this activity and review the contents as needed.

These recordings feature lectures and discussions with leading experts in cellular therapies. The goal of this oncology conference was to improve the knowledge, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients receiving cellular therapies for hematologic and non-hematologic disorders. The conference agenda included an in-depth discussion and analysis of the latest scientific findings and practice-changing advances in chimeric antigen receptor (CAR) based therapies. Expert faculty aimed to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

REGISTRATION FEES:

This activity is $0 for all.

Target Audience

  • Oncologists
  • Oncology fellows
  • Oncology nurses
  • Oncology nurse practitioners
  • Oncology physician assistants
  • Oncology pharmacists
  • Others who treat patients with hematologic malignancies and solid tumors

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
  • State the financial, physical and other barriers, review strategies to navigate these factors to optimize management of patients with cellular therapies
Course summary
Available credit: 
  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.
Course opens: 
09/09/2022
Course expires: 
09/09/2023
Cost:
$0.00

This educational activity features recorded videos from the live course titled - 2022 Cellular Therapy Conference held 9/9-10/2022.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.


Session 1 – General Concepts

15 minutes - History of CAR-T therapy - Dr. Tania Jain

15 minutes - CAR-T overview - Dr. Sagar Patel and Dr. Catherine Lee

20 minutes - Barriers to CAR-T access - Dr. Navneet Majhail

15 minutes - Academia – Community partnership - Dr. Daniel Couriel


Session 2 – CLL/NHL

15 minutes - CAR- T in CLL - Dr. Harsh Shah

10 minutes - CAR-T in B-NHL - Dr. Boyu Hu

15 minutes - CAR-T in indolent lymphomas - Dr. Daniel Ermann


Session 3 - ALL

25 minutes - CAR-T in pediatric B-ALL - Dr. Michael Pulsipher

25 minutes - CAR-T in adult B-ALL - Dr. Nitin Jain


Session 4 – Special topics

20 minutes - CAR-T in high-risk populations - Dr. Brad Hunter

15 minutes - The role of radiation in CAR-T - Dr. Randa Tao

20 minutes - COVID-19 and CAR-T - Dr. Hannah Imlay


Session 5 – Multiple myeloma

25 minutes - CAR-T in multiple myeloma - Dr. Brian McClune

20 minutes - Emerging cellular therapies in multiple myeloma - Dr. Douglas Sborov


Session 6 – Solid tumors

20 minutes - CAR-T in PCNSL and SCNSL - Dr. P. Connor Johnson

20 minutes - CAR-T in solid tumors - Dr. Umang Swami


Session 7 – Supportive care

20 minutes - CAR-T Toxicity management - Angela Kirk, PA-C

30 minutes - Infectious complications in CAR-T - Dr. Carlos Gomez

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

PLANNER(S)

Catherine Lee, MD has a financial relationship (Independent contractor) with Fresenius Kabi; financial relationship (Independent contractor) with Kite; financial relationship (Stock) with Kadmon; financial relationship (Grant Or Contract) with Incyte Corporation; financial relationship (Independent contractor) with Kadmon; financial relationship (Independent contractor) with Jazz Pharmaceuticals.

Sagar Patel, MD has a financial relationship (Grant Or Contract) with Medexus; financial relationship (Grant Or Contract) with CareDx; financial relationship (Grant Or Contract) with Kite Pharma.

SPEAKER(S)

Daniel Couriel, MD, MS, MBA has a financial relationship (Professional Services) with Incyte, Inc; financial relationship (Other) with Seagen, Inc.

Daniel Ermann, MD has no relevant financial relationships to disclose at this time.

Carlos Gomez, MD has no relevant financial relationships to disclose at this time.

Boyu Hu, MD has a financial relationship (Other) with TG Therapeutics; financial relationship (Other) with Bristol Meyer Squibb; financial relationship (Grant Or Contract) with Morphosys Ag; financial relationship (Other) with MJH Life Sciences; financial relationship (Grant Or Contract) with CRISPR Therapeutics; financial relationship (Grant Or Contract) with Caribou Biosciences; financial relationship (Other) with OncLive; financial relationship (Grant Or Contract) with Celgene/BMS; financial relationship (Grant Or Contract) with Genentech; financial relationship (Other) with ADC Therapeutics; financial relationship (Other) with Novartis; financial relationship (Grant Or Contract) with Repare Therapeutics.

Bradley Hunter, MD. MPH has a financial relationship (Professional Services) with Notable Labs; financial relationship (Professional Services) with Kite Pharma; financial relationship (Professional Services) with AbbVie; financial relationship (Professional Services) with ADC Therapeutics; financial relationship (Professional Services) with Genmab; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Novartis; financial relationship (Professional Services) with BMS.

Hannah Imlay, MD has no relevant financial relationships to disclose at this time.

Nitin Jain, MD has a financial relationship (Gift) with Genentech; financial relationship (Gift) with Beigene; financial relationship (Gift) with AbbVie; financial relationship (Gift) with Precision Bio; financial relationship (Gift) with Janssen; financial relationship (Gift) with Kite; financial relationship (Gift) with Fate Therapeutics; financial relationship (Gift) with Pharmacyclics; financial relationship (Gift) with AstraZeneca; financial relationship (Gift) with Cellectis.

Tania Jain, MBBS has a financial relationship (Other) with CTI Biopharma, SyneosHealth, Incyte; financial relationship (Other) with Care Dx, Bristol Myers Squibb, Incyte, Abbvie, CTI, and Kite.

Patrick Connor Johnson, MD has a financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with ADC Therapeutics; financial relationship (Independent contractor) with Seagen.

Angela Kirk, Physician Assistant has no relevant financial relationships to disclose at this time.

Catherine Lee, MD has a financial relationship (Grant Or Contract) with Incyte Corporation; financial relationship (Independent contractor) with Kadmon; financial relationship (Independent contractor) with Jazz Pharmaceuticals; financial relationship (Independent contractor) with Fresenius Kabi; financial relationship (Independent contractor) with Kite; financial relationship (Stock) with Kadmon.

Navneet Majhail, MD, MS, FASTCT has a financial relationship (Independent contractor) with Incyte; financial relationship (Independent contractor) with Anthem Inc.

Brian McClune, DO has no relevant financial relationships to disclose at this time.

Sagar Patel, MD has a financial relationship (Grant Or Contract) with Kite Pharma; financial relationship (Grant Or Contract) with Medexus; financial relationship (Grant Or Contract) with CareDx.

Michael Pulsipher, MD has a financial relationship (Other) with Bluebird; financial relationship (Other) with Gentibio; financial relationship (Other) with Equillium; financial relationship (Other) with Novartis; financial relationship (Other) with Medexus; financial relationship (Other) with Vertex.

Douglas Sborov, MD MS has a financial relationship (Professional Services) with GlaxoSmithKline; financial relationship (Professional Services) with Janssen; financial relationship (Professional Services) with Celgene; financial relationship (Professional Services) with Sanofi; financial relationship (Professional Services) with Abbvie.

Harsh Shah, D.O. has a financial relationship (Grant Or Contract) with BeiGene; financial relationship (Grant Or Contract) with Seattle Genetics.

Umang Swami, MD, MS has a financial relationship (Other) with Astellas; financial relationship (Other) with Seattle Genetics; financial relationship (Other) with Exelixis.

Randa Tao, MD has a financial relationship (Travel) with The Lynx Group; financial relationship (Other) with QED Therapeutics; financial relationship (Other) with Helsinn.

Important Information about Claiming CME for this activity:

If you participated in the live course titled - 2022 Cellular Therapy Conference on 9/9-10/2022 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that course on 9/9-10/2022. However, you can still enroll in this activity and review the contents as needed.

The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.

The Binaytara Foundation designates this enduring activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 575 Contact Hours.

ABSM Maintenance of Certificate Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

 

Available Credit

  • 5.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 5.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 5.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 5.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 5.75 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is $0 for all.

Cancellation Policy

You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.